{"id":"avibactam-avi","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"}]},"_chembl":{"chemblId":"CHEMBL1689063","moleculeType":"Small molecule","molecularWeight":"265.25"},"_dailymed":{"setId":"be1a6c99-d4b3-46d7-9e99-6e5f9fab556a","title":"EMBLAVEO (AZTREONAM AND AVIBACTAM) POWDER, FOR SOLUTION [ABBVIE INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Avibactam is a non-beta-lactam beta-lactamase inhibitor that works through a mechanism distinct from traditional inhibitors. It binds covalently to serine beta-lactamases and reversibly to metallo-beta-lactamases, preventing these enzymes from breaking down beta-lactam antibiotics. This allows beta-lactam drugs to remain active against otherwise resistant bacteria, restoring their therapeutic efficacy.","oneSentence":"Avibactam is a beta-lactamase inhibitor that protects beta-lactam antibiotics from enzymatic degradation by binding to and inactivating bacterial beta-lactamases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:57:16.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) in combination with ceftazidime"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in combination with ceftazidime"},{"name":"Complicated intra-abdominal infections (cIAI) in combination with ceftazidime"}]},"trialDetails":[{"nctId":"NCT05639647","phase":"PHASE2","title":"Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-04-18","conditions":"Gram-negative Bacterial Infections","enrollment":48},{"nctId":"NCT07268560","phase":"","title":"Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-12-25","conditions":"Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)","enrollment":100},{"nctId":"NCT06462235","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-09-25","conditions":"Gram-negative Bacterial Infection","enrollment":48},{"nctId":"NCT07478484","phase":"PHASE4","title":"Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB","status":"RECRUITING","sponsor":"Jing Zhou","startDate":"2026-03-31","conditions":"Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection","enrollment":144},{"nctId":"NCT06717594","phase":"","title":"PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2023-12-01","conditions":"Gram Negative Infections, Antimicrobial Resistance (AMR)","enrollment":60},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT05487586","phase":"","title":"Real-World Study of Ceftazidime Avibactam in China","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-10-20","conditions":"Hospital Acquired Pneumonia, Ventilator Acquired Pneumonia, Complicated Intra Abdominal Infections","enrollment":220},{"nctId":"NCT05413343","phase":"","title":"Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-06-01","conditions":"Severe Sepsis","enrollment":30},{"nctId":"NCT06593054","phase":"PHASE1","title":"To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-29","conditions":"Healthy","enrollment":13},{"nctId":"NCT06939829","phase":"PHASE4","title":"A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","status":"NOT_YET_RECRUITING","sponsor":"Southeast University, China","startDate":"2025-05-01","conditions":"Patients With Critically Ill Infections","enrollment":1200},{"nctId":"NCT03329092","phase":"PHASE3","title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-04-05","conditions":"Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia","enrollment":422},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT06651047","phase":"","title":"PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections","status":"RECRUITING","sponsor":"University of Bologna","startDate":"2024-07-09","conditions":"Gram Negative Infection, Antimicrobial Resistance (AMR)","enrollment":120},{"nctId":"NCT04774094","phase":"PHASE4","title":"Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-21","conditions":"Hospital-Acquired Pneumonia","enrollment":235},{"nctId":"NCT06528028","phase":"PHASE4","title":"Relationship Between Different Administration Regimens of Ceftazidime/Avibactam and Clinical Outcomes","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-07-01","conditions":"Anti-Infective Agent","enrollment":140},{"nctId":"NCT05258851","phase":"PHASE3","title":"Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2022-06-01","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":29},{"nctId":"NCT03580044","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-12-25","conditions":"Serious Bacterial Infection","enrollment":15},{"nctId":"NCT04973826","phase":"PHASE1","title":"Study to Assess the Pharmacokinetics, Safety and Tolerability of Aztreonam-Avibactam in Healthy Chinese Participants.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-20","conditions":"Healthy","enrollment":12},{"nctId":"NCT04486625","phase":"PHASE1","title":"Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal Impairment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-08-10","conditions":"Renal Insufficiency","enrollment":11},{"nctId":"NCT05850871","phase":"NA","title":"Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-01-06","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":427},{"nctId":"NCT04040621","phase":"PHASE1","title":"Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-06-15","conditions":"Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia","enrollment":4},{"nctId":"NCT03790176","phase":"PHASE1","title":"ZAVI APD ELF Protocol v2.2","status":"UNKNOWN","sponsor":"Markus Zeitlinger","startDate":"2018-10-01","conditions":"Peritonitis, Pneumonia","enrollment":20},{"nctId":"NCT02655419","phase":"PHASE2","title":"Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-05-19","conditions":"Complicated Intra-Abdominal Infections, cIAIs","enrollment":40},{"nctId":"NCT02475733","phase":"PHASE2","title":"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08-01","conditions":"Complicated Intra-abdominal Infections","enrollment":83},{"nctId":"NCT02497781","phase":"PHASE2","title":"Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-24","conditions":"Complicated Urinary Tract Infections","enrollment":97},{"nctId":"NCT01644643","phase":"PHASE3","title":"Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-01","conditions":"Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection","enrollment":345},{"nctId":"NCT01599806","phase":"PHASE3","title":"Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","enrollment":641},{"nctId":"NCT01689207","phase":"PHASE1","title":"To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Complicated Infection, Bacterial Infections","enrollment":222},{"nctId":"NCT01499290","phase":"PHASE3","title":"Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-03","conditions":"Complicated Intra-Abdominal Infection","enrollment":493},{"nctId":"NCT01808092","phase":"PHASE3","title":"A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-04","conditions":"Nosocomial Pneumonia (NP), Ventilator-associated Pneumonia (VAP)","enrollment":969},{"nctId":"NCT01595438","phase":"PHASE3","title":"Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10","conditions":"Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis","enrollment":598},{"nctId":"NCT01893346","phase":"PHASE1","title":"Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Systemic Infections","enrollment":35},{"nctId":"NCT01920399","phase":"PHASE1","title":"A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT01789528","phase":"PHASE1","title":"A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-08","conditions":"Pharmacokinetics, Open Label, CAZ-AVI","enrollment":48},{"nctId":"NCT01534247","phase":"PHASE1","title":"A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":418,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Avibactam (AVI)","genericName":"Avibactam (AVI)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avibactam is a beta-lactamase inhibitor that protects beta-lactam antibiotics from enzymatic degradation by binding to and inactivating bacterial beta-lactamases. Used for Complicated urinary tract infections (cUTI) in combination with ceftazidime, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in combination with ceftazidime, Complicated intra-abdominal infections (cIAI) in combination with ceftazidime.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}